Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck’s CEO to get $1.5 million Yearly Plus Incentives

By Pharmaceutical Processing | December 1, 2010

NEW YORK (AP) — Merck & Co. will pay its new CEO, Kenneth C. Frazier,
$1.5 million annually plus incentives, according to a filing with the Securities
& Exchange Commission.

The company named Frazier on Tuesday as Richard T. Clark’s successor as chief
executive effective Jan. 1. The regulatory filing was made later in the day.

Frazier, 55, joined the company in 1992 and was a long-time general counsel
until being named president of the company’s global human health unit in 2007.
He was promoted to president in April, putting him in line for the CEO
position.

Clark, 64, has been CEO since 2005 and was expected to retire, per company
policy, when he turns 65 in March. Merck is based in Whitehouse Station,
N.J.

Frazier will join the board of directors as part of the promotion and Clark
will remain chairman of the board.

Along with his annual salary, Frazier will receive an annual cash incentive
award of 150 percent of his annual base salary and receives a long term
incentive grant of $7.5 million. That grant will include restricted stock units,
stock options and performance share units.

He will continue to participate in the company’s employee benefit plans and
programs.

Clark, meanwhile, will receive an annual base salary of $1.5 million with a
target annual cash incentive of 125 percent of the base salary. He will receive
a long-term incentive grant of restricted stock units worth $6 million and
continue to participate in the company’s benefit plans.

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE